Fig. 1From: Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myelomaHyponatraemia during anti-MM treatment and response to tolvaptan therapyBack to article page